Pharmacist-driven CGM Use in the Uninsured Population

Virginia Commonwealth University28 enrolled

Overview

This is a pilot study. The purpose is to (1) provide access to continuous glucose monitoring (CGM) to patients (purchased through a grant) and (2) systematically record and analyze the results of the glucose monitoring by the clinical pharmacists at the clinic.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus

Interventions

FreeStyle LibrePro CGMDEVICE

a professional CGM device will be worn by the participant for up to 14 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. adult 18 years of age or older 2. diagnosis of Type 1 or Type 2 diabetes 3. A1c greater than 8% 4. prescribed basal insulin plus either prandial insulin or a glucagon-like peptide-1 (GLP-1) receptor agonist Exclusion Criteria: 1. pregnant or breast-feeding 2. on dialysis 3. not appropriate for CGM use based on clinical judgment by the investigators 4. patients with limited English proficiency

Locations (1)

Virginia Commonwealth University

Richmond, Virginia, United States

Outcomes

Primary Outcomes

Change in A1c

Change in A1c will be used to assess glycemic control

Time frame: Baseline to week 12

Secondary Outcomes

Medication Changes

Data will be collected on what medication changes are made (changes in types of medications and doses)

Time frame: Baseline to week 12

Glycemic Variability

Data collected by the CGM, such as time-in-therapeutic range, will be evaluated to assess glycemic variability during the 14 day period of wearing the CGM

Time frame: Baseline to week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.